Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Robert J KreitmanClaire DeardenPier Luigi ZinzaniJulio DelgadoTadeusz RobakPhilipp D le CoutreBjørn T GjertsenXavier TroussardGail J RobozLionel KarlinDouglas E GladstoneNataliya Kuptsova-ClarksonShiyao LiuPriti PatelFederico RotoloEmmanuel MitryIra PastanFrancis Gilesnull nullPublished in: Journal of hematology & oncology (2021)
ClinicalTrials.gov identifier: NCT01829711; first submitted: April 9, 2013. https://clinicaltrials.gov/ct2/show/NCT01829711.
Keyphrases
- acute myeloid leukemia
- acute lymphoblastic leukemia
- single cell
- computed tomography
- clinical trial
- cell therapy
- phase iii
- bone marrow
- image quality
- multiple myeloma
- diffuse large b cell lymphoma
- contrast enhanced
- hodgkin lymphoma
- dual energy
- phase ii
- positron emission tomography
- magnetic resonance
- mesenchymal stem cells
- open label